Resistance to immune checkpoint blocker drug linked to metabolic imbalance

A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute, in collaborative work with the Broad Institute of MIT and Harvard.

source https://www.lifetechnology.com/blogs/life-technology-medical-news/resistance-to-immune-checkpoint-blocker-drug-linked-to-metabolic-imbalance